Cancer name Pancreatic Cancer
Cancer Type PAAD
Immunotherapy type Immune Checkpoint Therapy;Immunostimulant OR Targeting Therapy
Treatment anti-PD-L1
Drugstatus NA
Drugbank ID NA
Checkpoints PD-L1
Signature Type Cell
Signature CD8+ CTL
Official Symbol NA
Mode of action CE_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description Analysis of tumor tissues revealed that verticillin A fur-ther increased anti-PD-L1 Mab-induced CD8+ CTL tumor infil-tration (P<.006–<.001) in both PANC02-H7 and UN-KC-6141 tumors and CTL activation as measured by IFNγ level in PANC02-H7 tumors (P<.02) in vivo. These observations suggest that pancreatic tumor growth control in vivo and anti-PD-L1 immunotherapy efficacy depend on FasL and CTLs.
PMID 28131992
Title The MLL1-H3K4me3 Axis-Mediated PD-L2 Expression and Pancreatic Cancer Immune Evasion